257 related articles for article (PubMed ID: 16859388)
1. Investigational agents for sickle cell disease.
Okpala I
Expert Opin Investig Drugs; 2006 Aug; 15(8):833-42. PubMed ID: 16859388
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
3. New therapies for sickle cell disease.
Okpala IE
Hematol Oncol Clin North Am; 2005 Oct; 19(5):975-87, ix. PubMed ID: 16214656
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
6. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
8. Sickle cell disease: progress towards combination drug therapy.
Pace BS; Starlard-Davenport A; Kutlar A
Br J Haematol; 2021 Jul; 194(2):240-251. PubMed ID: 33471938
[TBL] [Abstract][Full Text] [Related]
9. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Ataga KI; Staffa SJ; Brugnara C; Stocker JW
Br J Haematol; 2021 Mar; 192(5):e129-e132. PubMed ID: 33527340
[No Abstract] [Full Text] [Related]
10. Strides made in red blood cell disorders, but substantial barriers to care remain.
Hampton T
JAMA; 2008 Jan; 299(4):395-6. PubMed ID: 18230771
[No Abstract] [Full Text] [Related]
11. Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA; Vichinsky E
Br J Haematol; 2021 Nov; 195(4):518-522. PubMed ID: 34131897
[TBL] [Abstract][Full Text] [Related]
12. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Wood KC; Granger DN
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
[TBL] [Abstract][Full Text] [Related]
13. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
[TBL] [Abstract][Full Text] [Related]
15. Advances in sickle cell disease treatment: from drug discovery until the patient monitoring.
dos Santos JL; Lanaro C; Chin CM
Cardiovasc Hematol Agents Med Chem; 2011 Apr; 9(2):113-27. PubMed ID: 21401492
[TBL] [Abstract][Full Text] [Related]
16. Fetal haemoglobin induction in sickle cell disease.
Paikari A; Sheehan VA
Br J Haematol; 2018 Jan; 180(2):189-200. PubMed ID: 29143315
[TBL] [Abstract][Full Text] [Related]
17. Sickle cell anaemia: current therapies.
Vermylen C
Transfus Apher Sci; 2013 Oct; 49(2):151-4. PubMed ID: 23954416
[TBL] [Abstract][Full Text] [Related]
18. Treatment Options for Sickle Cell Disease.
Meier ER
Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275
[TBL] [Abstract][Full Text] [Related]
19. Haemoglobin F modulation in childhood sickle cell disease.
Trompeter S; Roberts I
Br J Haematol; 2009 Feb; 144(3):308-16. PubMed ID: 19036119
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Treatment of Sickle Cell Disease.
Kapoor S; Little JA; Pecker LH
Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
